Sanxing Medical
Launch date
Employees
Market cap
€5.7b
Enterprise valuation
€5.6b (Public information from Sep 2024)
Share price
CNY32.35 601567.SS
Ningbo Zhejiang (HQ)
Financials
Estimates*
| CNY | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 7.1b | 7.0b | 9.1b | 11.5b | 14.3b | 17.6b | 21.4b |
| % growth | 5 % | (1 %) | 30 % | 26 % | 25 % | 23 % | 22 % |
| EBITDA | 1.5b | 1.1b | 1.5b | 2.6b | 3.2b | 4.0b | 4.6b |
| % EBITDA margin | 21 % | 16 % | 16 % | 22 % | 23 % | 22 % | 21 % |
| Profit | 956m | 690m | 948m | 1.9b | 2.3b | 2.8b | 3.4b |
| % profit margin | 13 % | 10 % | 10 % | 17 % | 16 % | 16 % | 16 % |
| EV / revenue | 1.3x | 3.2x | 2.1x | 2.5x | 3.3x | 2.6x | 2.2x |
| EV / EBITDA | 6.2x | 20.1x | 12.7x | 11.3x | 14.3x | 11.7x | 10.1x |
| R&D budget | 313m | 294m | 327m | 471m | - | - | - |
| R&D % of revenue | 4 % | 4 % | 4 % | 4 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
| Total Funding | - | ||
